CAR-T cells are a remarkable therapeutic innovation of recent years. The Alcimed Healthcare team has been exploring the CAR-T cell therapy market for nearly 10 years and supports its clients in their innovation and development projects for these innovative therapies, in optimizing market access and patient care management.
They trust us
The challenges related to CAR-T cell therapy
The CAR-T cells market, valued at nearly €700 million in 2019, is experiencing strong growth and could reach €3 billion by 2025. In fact, more than 250 pharmaceutical companies around the world are working on research into chimeric antigen receptor T cells.
However, while the market is promising, this innovative therapy is not without its challenges for the pharmaceutical industry. These challenges include:
Today, due to the novelty of the CAR-T cell treatment procedure, its complexity, the still frequent side effects and the need to set up very structured interactions between hospital departments, the use of CAR-T cells are still limited to hospitals that have been specifically authorized to take care of patients receiving these treatments.
How can we ensure effective coverage of the territories despite the need to centralize dispensing? How can we simplify the procedures to make the treatment more accessible?
These innovative drugs raise new questions in terms of production circuits, market access, delivery and patient care. Therefore, the arrival of these therapeutic advances requires the rethinking of the supply chain, production models, and the distribution of value throughout the treatment chain. At the same time, studies are underway to develop these therapies from donor cells and not from the patient himself, which would considerably modify the production constraints.
How to better integrate the production chain into the value chain? What are the most appropriate financing and support models for this innovative therapy?
Numerous clinical trials are underway to evaluate the efficacy of CAR-T cell therapies beyond hematological cancers, towards the treatment of solid tumors.
What are the priority areas of development? How to differentiate the research areas in order to maximize the chances of success?
How we support you in your projects related to CAR-T cell therapy
For nearly 10 years, Alcimed has been supporting its clients on many issues related to CAR-T cell therapies in hematology, oncology and more broadly in immunotherapy. Indeed, we have carried out dozens of projects in this field for different stakeholders such as:
- National, European and international institutions and research centers.
- European and North American biopharmaceutical and pharmaceutical companies
- Biotech companies
The diversity of our clients, of the geographic fields we explore, and the types of projects we carry out, give us a global and in-depth understanding of the issues addressed in the field of CAR-T cell therapies.
In this context, Alcimed supports its clients in particular in exploring this new ecosystem and in analyzing the place and role of industrial players in terms of a value proposition. We have also supported public institutions to position themselves as European champions of CAR-T cells, but also industrial players to prepare the launch of CAR-T cell products, to understand the scope of CAR-T cells manufacturing possibilities, to evaluate market access opportunities, pricing or reimbursement of these treatments.
Examples of recent projects carried out for our clients in CAR-T cell therapy
Preparation for the launch of a new CAR-T cell therapy in the United States and EuropeWe supported a leading stakeholder in the field of CAR-T cells in preparing for the launch of its new treatment and in defining its market access strategy in the United States, Canada and Europe.CAR-T cells are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare ficilities are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to understand and identify which centers would have the capacity to deliver CAR-T cells, among more than 200 care centers in the United States, Canada and Europe.Then, the analysis of the barriers to approval in the relevant markets made it possible to define the actions to be implemented to develop the skills of each center, and thus ensure access to their new CAR-T cell therapy.
Regulatory framework analysis and market access strategy for a CAR-T cell therapyWe have supported a global pharmaceutical leader in the characterization of European and American healthcare establishments in order to assess their degree of maturity for the administration of CAR-T cells.Thanks to the analysis of the new regulatory framework surrounding the use of CAR-T cells and to the deciphering of the positioning of public healthcare establishments and industrial players in this field, Alcimed enabled its client to better understand the possible regulatory changes as well as the challenges of qualifying centers, defining its market access strategy and adapting its internal structure accordingly.
Mapping and analysis of the care pathway for CAR-T cells therapiesWe supported a pharmaceutical company in France in the analysis of the modalities of referral of patients eligible for CAR-T cell therapy to specialized centers.We first mapped patient referrals to the 6 major centers of excellence in France for CAR-T cell therapy, then characterized the referral flows (criteria and volumes) and the relationships between peripheral centers and centers of excellence.By identifying the criteria for addressing patients and the levers to be activated to promote cooperation and coordination between those involved in the pathway, our client was able to understand the opportunities for improvement and the barriers to be faced in order to guarantee the optimal functioning of the process.
Development of the Brand Plan for the launch of two CAR-T cell therapies
We supported the teams of a pharmaceutical company in France in their preparation for the launch of two CAR-T cell gene therapy products and in defining their brand plan.
Because of the novelty of these products, it was first of all a matter of challenging and building a shared vision in the team of the launch strategy for these products (medical, marketing, market access, etc.), over the course of several workshops.
The structuring of these ideas was then a key step in making this vision concrete and operational, and helped accelerate the formalization of the Brand Plan co-constructed by all.
You have a project?
To go further
4 key facts steering the future direction of CAR T-Cell therapies
CAR T-cell therapies gain more and more attention as being innovative immunotherapy options for cancer patients. Although being researched for years, the approval reach of new treatments is yet ...
Optogenetics: towards gene and light therapies?
What is optogenetics and what are the medical applications being developed? Optogenetics works by introducing into the cells a gene coding for a photosensitive protein, which is then activated by ...
Autologous CAR-T cell therapies: 3 ways pharma companies are addressing their manufacturing challenges
There are many challenges related to the manufacturing and supply chain needs to produce autologous CAR-T cell therapies. How do they impact delivery times and cost to the patient? How are some ...
Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow’s world hand in hand with our clients.
In 2018, the European marketing authorizations for Kymriah® (Novartis) and Yescarta® (Gilead) represented the advent of an innovative therapeutic option for the treatment of certain hematological cancers. This new gene therapy, the CAR-T cell (Chimeric Antigen Receptor T-Cells) therapy, consists of using the patient’s own immune cells as medicine. Concretely, these cells, T lymphocytes, are removed, then genetically modified to specifically destroy cancer cells, then injected back into the patient. Therefore, CAR-T cell therapy can be categorized as an immunotherapy.
After a promising start, the marketing of three other CAR-T cells and an impressive list of candidates in hematology (and in the longer term in solid tumors), predicts a bright future for these innovative CAR-T cells drugs.